CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ:CRIS), a drug development company focused on developing proprietary targeted medicines primarily for cancer treatment, today announced that it will release its first quarter financial results on Wednesday, April 30, 2008 before the market opens. The Company will also hold a conference call on the same day at 9:00 A.M. Eastern time to discuss the progress of GDC-0449, which is an orally-administered small molecule inhibitor of the Hedgehog pathway that its collaborator Genentech is currently preparing for Phase II clinical testing. The Company’s management will also discuss CUDC-101 and the Company’s other targeted cancer programs, Curis’ financial results and additional corporate activities. Daniel Passeri, President and Chief Executive Officer of Curis, will host the call.
